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ABSTRACT
DNA-binding drugs have numerous applications
in the engineered gene regulation. However, the
drug-DNA recognition mechanism is poorly
understood. Drugs can recognize specific DNA
sequences not only through direct contacts but
also indirectly through sequence-dependent
conformation, in a similar manner to the indirect
readout mechanism in protein-DNA recognition.
We used a knowledge-based technique that takes
advantage of known DNA structures to evaluate
the conformational energies. We built a dataset of
non-redundant free B-DNA crystal structures to
calculate the distributions of adjacent base-step
and base-pair conformations, and estimated the
effective harmonic potentials of mean force (PMF).
These PMFs were used to calculate the conforma-
tional energy of drug-DNA complexes, and the
Z-score as a measure of the binding specificity.
Comparing the Z-scores for drug-DNA complexes
with those for free DNA structures with the same
sequence, we observed that in several cases the
Z-scores became more negative upon drug binding.
Furthermore, the specificity is position-dependent
within the drug-bound region of DNA. These
results suggest that DNA conformation plays an
important role in the drug-DNA recognition.
The presented method provides a tool for the
analysis of drug-DNA recognition and can facilitate
the development of drugs for targeting a specific
DNA sequence.
INTRODUCTION
The control of the gene expression by DNA-binding
drugs is of great interest in molecular biology and
medicine since the capability of some drugs to switch on
or oﬀ the gene expression can help in the treatments of
genetic diseases, infections by antibiotic-resistant bacteria,
or cancer (1–3).
The drug discovery process requires large collections
of molecules, which are initially tested with high
throughput screening (4,5). Therefore, it is interesting to
provide methods that eliminate as early as possible the
poor drug candidates. This screening includes approaches
such as ADMET (absorption, distribution, metabolism,
excretion and toxicity) (6). Tools, such as the Lipinski rule
of ﬁve (7), help to ﬁlter non-oral bioavailable drug
candidates. However, additional tools are needed to
predict the drug speciﬁcity accurately, which motivated
the present study.
Whereas the ﬁrst golden era of cancer drug development
was marked by the discovery of the therapeutic activity
of the ﬁrst DNA alkylating agent (8), the second golden
era aims to provide targeted therapies designed speciﬁcally
to tackle the molecular abnormalities responsible for
cancer (9). In this sense it is important to provide tools
that estimate the DNA sequence-dependent speciﬁcity
of the DNA binding drugs. For example, if a drug binds
in an indiscriminate way to many DNA sequences, this
could have a fatal consequence since it can modify the
expression of vital gene products. The sequence-dependent
speciﬁcity plays a key role in the search of ‘the right
medicine to the right patient’ of the individualized
medicine with pharmacogenomics (10,11). The speciﬁcity
of the drug-DNA binding is a key point in the drug
design since many compounds obtained by structure-
based drug design show inappropriate ADMET properties
(12). Finally, the X-ray analysis of the drug-DNA crystal
structures does not provide quantitative estimates of
the relative importance of the molecular contacts or of
the relative contributions of speciﬁc and non-speciﬁc
interactions to the total aﬃnity of speciﬁc DNA binding
(13,14). Therefore, it would be interesting to provide
a tool, as the one proposed here, for quantifying the
binding speciﬁcity.
The mechanisms of drug binding to proteins and to
DNA may share some similarities, along with some
diﬀerences. Traditionally, drug-protein binding is
explained by either the Fischer’s ‘lock and key’ principle
(15) or the Koshland’s ‘induced ﬁt’ model (16). The
extrapolation of such models to drug-DNA complexes is
not straightforward since the DNA has no formal active
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models, such as the ‘pre-existing equilibrium/conforma-
tional selection’ model, have been proposed to explain
the conformational changes involved in signal transmis-
sion between protein functional sites (18) and between
protein-drug complexes. While in the induced ﬁt mecha-
nism, the ligand is proposed to induce a conformational
change by interaction, the preexisting equilibrium hypoth-
esis postulates that the native state of a protein is deﬁned
by an ensemble of closely related conformations that
coexist at equilibrium, and that the ligand binds selectively
to an active conformation (18). In this sense, our studies
on molecular dynamics of DNA structures (19) have
shown that the DNA structures ﬂuctuate around some
equilibrium points, and some of these points could be
in favor of conformations that facilitate ligand binding
(of drugs or proteins).
For the analysis of the drug-DNA binding speciﬁcity,
we also use an analogy with the direct and indirect readout
mechanisms in protein-DNA recognition (20). The reg-
ulatory proteins recognize speciﬁc DNA sequences mainly
by the way of direct readout through base-amino acid
contact, and indirect readout through DNA conformation
and ﬂexibility. In the direct readout, the free energy of the
intermolecular interaction between bases and amino acids
determines the stability and speciﬁcity of the protein-
DNA complex. In the indirect readout, the change in the
intramolecular conformational energy of DNA upon
complex formation determines the sequence speciﬁcity.
Similar to proteins, a drug may use direct and indirect
readout to recognize a speciﬁc sequence. We concentrate
our study on the indirect readout mechanism in drug-
DNA recognition through sequence-dependent DNA
conformation. A number of drugs have already been
designed to bind speciﬁc short DNA sequences (Table 2 in
Supplementary Data).
The analysis of sequence-dependent conformational
energy of DNA can provide helpful hints in the design
of DNA-binding drugs that modify the DNA conforma-
tional state. According to the common practice in DNA
structural analysis (21,22), we approximate the DNA
molecule as an elastic object with several degrees of
freedom between adjacent rigid bases. We deﬁne the base
step as a group of two consecutive base pairs in a double-
stranded helical DNA structure. The local conformation
of the DNA is identiﬁed at each location of a base-pair
(from complementary strands) in terms of known defor-
mations. The base-step conformations describe the stack-
ing geometry of a dinucleotide step from a local
perspective (21–23) (see Figure 5 in Supplementary
Data). Each of these degrees of freedom is characterized
by a degree of ﬂexibility. The observed deformations,
compared with an average structure, are related to the
conformational energy. We adopt a knowledge-based
method using the analysis of known free DNA structures
to derive statistical potentials of the DNA conformational
energy.
The total conformational energy of DNA can be
approximated with a weighted summation of all the
base-pair and base-step energies. Olson et al. (24) used a
harmonic function to calculate the conformational energy
along each base-step conformational parameter. We
obtained the force constants from covariance
matrices between the 12 conformational parameters
generalizing the method of Olson et al. (24) for the 6
base-step conformational parameters from a dataset of
free B-DNA crystal structures, and quantiﬁed the
speciﬁcity of the indirect readout by using a sequence-
structure threading method (20). During the sequence-
structure threading, the original sequence in the
DNA structure was replaced by random sequences to
calculate a Z-score, i.e. the energy with respect to the mean,
normalized by the standard deviation, as a speciﬁcity
measure. We used free B-DNA crystal structures with
the same DNA sequence as known drug-DNA complexes
to calculate the Z-score as a reference. This enabled us
to evaluate the speciﬁcity of drug-DNA complex in
comparison with the corresponding free DNA structure.
MATERIALS AND METHODS
Data selection
The drug-DNA complex crystal structures were taken
from the annotated list of the Nucleic Acid Database
(NDB http://ndbserver.rutgers.edu) (25) (Table 3 in
Supplementary Data). The annotated lists with the
information about the type of the drug (intercalator or
groove binders) are also from the NDB. The binding mode
was automatically detected by the method introduced
below. To build a reference set of experimental free
B-DNA crystal structures, we used the corresponding
annotated list from NDB (Table 4 in Supplementary
Data).
For each ﬁle in each list, we chose the ﬁrst biological
unit structure and downloaded its ﬁle from the Biological
Units repository of Protein Data Bank (PDB) (http://
www.rcsb.org/pdb/) (26). The 3DNA software (23) was
used to obtain the base-pair and base-step conformational
parameters. For potential of mean force (PMF) calcula-
tion, we built a dataset of non-redundant free B-DNA
crystal structures, clustering the DNA sequences and
selecting the structure with the best resolution for the
clusters with more than one structure of the same
sequence. The dataset was pre-ﬁltered by applying the
following criteria (27). Eliminate the non-B-DNA base
steps (these were discriminated using the projection of the
phosphorus atom onto the z-axis of the dimer middle
frame (23,28)); delete anomalous conﬁguration with
outlier values in their conformational coordinates to
eliminate kinks and other defective structural states;
eliminate the non-standard bases (bases diﬀerent from
A, C, G, T). For the calculation of PMF, we took only a
half of the symmetric structure in repeated and palin-
dromic sequences; eliminate the 50 and 30 DNA terminals
to reduce the boundary eﬀects; and delete the base steps
that are not in blocks of 3 consecutive steps, to consider
local DNA regions without intercalated distortions.
Automatic classification of drug-DNA binding modes
To facilitate the DNA-drug binding analysis, we auto-
mated the classiﬁcation of the binding modes with a
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of DNA. We consider that there exists a contact between a
drug atom and a DNA atom when the inter-atomic
distance is <3.5A ˚ . We classiﬁed the DNA atoms into four
local regions (minor groove, major groove, backbone and
rest), as shown in Figure 1. The binding mode is deﬁned as
the argument that maximizes the function:














where #cov is the total number of covalent links in the
DNA-drug complex (obtained as the number of links with
the heteroatoms (HETATM) and atoms in the CONECT
ﬁeld of the PDB ﬁle), and #min, #maj and #int are the
total numbers of drug contacts with the minor groove,
major groove and intercalator atoms. The number
of contacts with intercalator atoms, #int, is deﬁned as
#min+ #maj+#res, where #res is the total number of
contacts with the rest of the atoms not belonging to any of
the DNA local regions deﬁned in Figure 1. The numbers
in the denominators of Equation (1) are normalization
factors that account for the number of atoms of each local
region in every DNA base pair. The additional inter-
calator factor 1.5 used in the normalization of the total
number of intercalation contacts accounts for the fact that
the intercalating drugs can make contacts with the two
consecutive base pairs between which they insert them-
selves. In asimple approximation of uniform rise values for
all base steps, the normalization factor for the intercalator
atoms should be two since a drug atom can make contacts
with the lower and the upper bases of the interstep space.
However, the drug atoms do not always make contacts
with the two base pairs that circumvent them. Thus, the
value 1.5 for the intercalator was adjusted empirically.
Derivations ofconformational energies andZ-scores
In contrast to our previous approach for the case of free
DNA structures (19), we calculated the energy taking into
account not only the base-step conformational state but
also the base-pair conformation. The conformational
energies of each central dinucleotide are estimated by
approximating the energy of the ﬂuctuations of each type s
of 10 unique base steps (see bottom Figure 5 in
Supplementary Data), with a harmonic function as in
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constants impeding the deformations of the given dinu-
cleotide d base step of type s. The 6-dimensional PMF F
s
for each type s can be calculated based on the quasi-
inverse-harmonic analysis from the covariance matrix of
conformational ﬂuctuations (24). For more detailed
description, see Supplementary Data.
Setting arbitrarily the minimum value energies e
sðdÞ
0
equal to 0, the total base-step energy of the structure
is Es ¼
PLD 1
d¼2 esðdÞ, where LD is the number of dinucleotide
pairs. Whereas the building blocks to calculate the base-
step conformational energy are dinucleotides, for the base
pairs they are mononucleotides. For the base-pair
conformational coordinates p of each mononucleotide m
(see top Figure 5 in Supplementary Data), we apply also
Equation (2), substituting the base-step coordinates of
each dinucleotide s(d) by the base-pair coordinates of each
mononucleotide p(m). The base-pair PMF F
p can be
calculated from the covariance matrix similarly. We
denote the total base-pair energy of the structure as
Ep ¼
PLM 1
m¼2 epðmÞ, where LM is the number of mono-
nucleotide pairs (the sequence length).
Once the base-pair and base-step energies are calcu-
lated, we combine them to calculate the total energy.
However, the statistical potentials derived from diﬀerent
kinds of datasets cannot be simply added to create the
total potential because the derivation of these empirical
Figure 1. Classiﬁcation of the non-hydrogen atoms of the four DNA
standard bases according to the type of contacts in DNA-drug
complexes. The atoms involved in minor groove contacts are
represented in red, the atoms involved in major groove contacts in
blue, the atoms involved in backbone contacts in black and the rest of
the atoms in green. The contact-inﬂuencing region of each atom is
shown with equispaced concentric circles with radii ranging from 1A ˚
to 3.5A ˚ .
378 Nucleic Acids Research, 2008, Vol. 36, No. 2energies is based on diﬀerent statistics (total number of
data, average and standard deviation). Thus, the energy
scales may be diﬀerent and a simple summation is not
allowed. Instead, we must combine their potentials with a
weighting factor c. Thus, we deﬁne the total conforma-
tional energy E of the structure as the weighted sum of
base-step E
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where the weighting coeﬃcient c ranges between 0 and 1.
This coeﬃcient is determined by maximizing the magni-
tude of total Z-score, i.e. in the sequence-structure
threading method, the Z-score is calculated from
random sequences rnd, and a value of c is sought that
produces the highest total Z-score. The value of c that
fulﬁls that requirement is determined by the following
equation:
c ¼
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where  
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rnd are the average and the standard
deviation of the base-pair energies,  s
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average and the standard deviation of the base-step
energies, and  
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. For the set of
drug-DNA crystal structures chosen in the Section ‘‘Data
selection’’, the average value of c is 0.72 with standard
deviation 0.21. A detailed explanation of the algorithm for
the Z-score calculations by sequence-structure threading is
shown in Supplementary Data.
RESULTS AND DISCUSSION
Automatic classification ofthe drug-DNA binding modes
The drug-DNA binding modes are commonly classiﬁed
into two categories: (i) Covalent binding (e.g. acridine),
(ii) Non-covalent binding, subdivided into two binding
modes: intercalative binding (e.g. nogalamycin), and
groove binding (e.g. berenil). X-ray diﬀraction and
nuclear magnetic resonance (NMR) spectroscopy are not
straight forward to determine the binding mode since the
results of these structural techniques are often precluded
by lack of site-speciﬁcity, rapid exchange or multiple
binding modes (13). Our automatic classiﬁcation method
of the drug-DNA binding mode compared with the
annotated list from NDB of 195 drug-DNA crystal
structures proved successful in the classiﬁcation of
almost all the structures, except for 7 PDB structures
(Table 5 in Supplementary Data). Interestingly, the
incorrectly classiﬁed structures have some covalent bind-
ings, even though not all of them are annotated as
covalent drugs. Thus, this method is very useful for
classifying the binding mode without looking at the
detailed structure, and for correlating the structure and
speciﬁcity in drug-DNA recognition.
Hoechst 33258, berenil and 40,6-diamidino-2-phenylin-
dole (DAPI) bind preferentially to the minor groove of AT
sequences but can also interact with GC sequences by a
mechanism that remains so far controversial (29). Electric
linear dichroism data support the hypothesis that such
drugs interact with GC sites via a non-classical intercala-
tion process (29). Our binding mode prediction is based
only on the crystal structure and for all the available
crystal structures of Hoechst 33258, berenil and DAPI, it
predicts groove-binding mode. This does not mean that
the real binding mode is always the same as observed in a
crystal; techniques such as electric linear dichroism (29) or
NMR(30) provide a dynamic view of the underlying
physical mechanism that is absent in the crystal studies.
Nevertheless, our binding mode prediction method can
give insight (when the coordinates of crystal structures are
available) into the binding mode analysis.
Conformational energy Z-scores by sequence-structure
threading
To analyze the conformational properties of drug-DNA
complexes, we collected structures with diﬀerent drugs
binding to the same DNA sequence, and used the above
method to classify automatically the drug binding modes.
We analyzed the capability of the PMF matrices
calculated with diﬀerent types of conformational coordi-
nates (base pair, base steps and the combination of both)
to estimate the binding speciﬁcity of drug-DNA com-
plexes. Figure 2 shows the results for the intercalator and
groove binder drugs. The diﬀerence, Z Z
p, between the
base-pair-based Z-score, Z
p, and the Z-scores based on
the combination of conformational coordinates, Z,i s
shown in Figure 2b. The base-pair-based PMF shows in
almost all of the cases worse speciﬁcity than the PMF
based on the combination of conformational coordinates.
Therefore, base pairs alone are not very reliable to
estimate speciﬁcities. The combination of base pair with
the base-step conformational coordinates has a positive
eﬀect on the speciﬁcity since generally the Z-scores
obtained from the combination of coordinates show
higher speciﬁcity (larger negative Z-scores) than the
base-step-based Z-scores (Figure 2c).
This result indicates that the base-step and base-pair
energies contain independent information. If both the
energies were totally dependent or correlated, the magni-
tude of the total Z-score would not increase. The energy of
base pair was assumed to be additive with respect to
each base, whereas the energy of base steps was derived
from base step, i.e. dinucleotide cooperative eﬀect is
involved in the latter. Therefore, we expect that the total
Z-score would increase by the combination of the
energies. Figure 2 shows that the magnitude of the total
Z-score calculated for many drug-DNA complexes, in
which the Z-scores for base pair and base steps are both
negative, did indeed increase. Therefore, in the rest of this
work we analyze the PMF calculated as a combination of
base-pair and base-step conformational coordinates to
analyze the speciﬁcity of the drug-DNA binding.
We tested the extent to which the energy corresponding
to the large deformations in DNA induced by drug
Nucleic Acids Research,2008, Vol. 36,No. 2 379binding can be treated with harmonic models, and
performed the Jarque–Bera hypothesis test to check
for the normality (31) of the conformational energy
landscape of each drug-DNA complex. The energy
landscape is obtained applying the sequence-structure
threading method for each drug-DNA complex (see
Supplementary Data). For each of 1000 random
sequences, we calculate the weighted sum of conforma-
tional energies, using Equation (3).
For each 1000-dimensional energy vector obtained with
the sequence-structure threading method, we applied the
Jarque–Bera hypothesis test for composite normality with
signiﬁcance level a=0.1%. The critical values are
computed with N Monte-Carlo simulations, where N
was chosen large enough to ensure that the Monte-Carlo
standard error  MC ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
pð1   pÞ=N
p
is <0.01. We obtained
that 38.1% of the intercalators possess a Gaussian energy
landscape (the average of their p-values is 0.02), whereas
62.2% of the groove binders have a Gaussian distribution
(and the average of their p-values is 0.09). These results
mean that in a signiﬁcant percentage of the cases (slightly
over the half), the conformational energy of the drug-
DNA complexes behaves in a harmonic way. Thus, it
might not be possible to apply the present harmonic
models if large deformations are involved. The result also
showed that the groove binder drug complexes behave in a
more harmonic way than the intercalator drug complexes.
We analyzed the DNA conformational changes induced
by the drug interactions. The covalent binding drugs
change dramatically the DNA conformations in such a
way that the harmonic PMF hypothesis may not be
applicable for the distorted region. Also, intercalators
may deform DNA in a potentially non-harmonic manner
by changing sugars puckers and backbone sub-states.
This was corroborated by the Jarque–Bera hypothesis test
of composite normality over the conformational energy
landscape obtained with the sequence-structure threading
method, which revealed that in the analyzed crystal
structures the groove binder drug-DNA complexes have
much higher percentage of Gaussian energy landscape
(62.2%) than the intercalator drug-DNA complexes
(38.1%). Nevertheless, the Z-scores can be calculated for
almost all of the intercalating drug structures available in
the NDB. The groove-binding drugs do not signiﬁcantly
perturb the DNA structure. The Z-scores are shown in
Tables 6 (groove binders) and 7 (intercalators) in
Supplementary Data and in panel (a) of Figure 2. This
panel also shows that the Z-scores obtained with PMF
from the combination of base pairs and base steps of the
groove binder drug-DNA complexes are smaller (more
speciﬁc) than the Z-scores of the intercalator drug-DNA
complexes. The average (and standard deviation) of the
groove binder drug-DNA complexes is  2.47 (1.11),
whereas for the intercalators is  1.29 (1.28). Although
the application of the harmonic PMF to intercalators is
less reliable, this result implies that the conformational
state of the DNA after binding is less speciﬁc than in the
case of the groove binder drugs. This result is indeed in
agreement with experimental results, which have shown
that intercalators do not generally have a pronounced
interaction with speciﬁc base sequences (32).
The DNA sequence itself may bias the Z-score. Thus,
we searched the NDB for free B-DNA crystal structures
with the same DNA sequence as that of the drug-DNA
complexes, and compared their conformational states
and Z-scores. To remove the eﬀect of self-contributions in
the free B-DNA structures, we carried out a jack-knife
procedure: when deriving the Z-score of each free B-DNA
structure, we recalculated the PMF matrices using a
dataset from which we removed the corresponding
Figure 2. Contribution of the Z-scores from diﬀerent types of PMFs to the global speciﬁcity of the binding modes. (a) Z-scores obtained with PMF
from the combination of base pairs and base steps (circle), base pairs (plus symbol) and base steps (square). The horizontal lines mark the Z-score
averages for the combination of base pairs and base steps (black), base pairs (red) and base steps (blue). (b) Z-scores obtained from the combination
of base pairs and base steps, Z, minus Z-scores obtained only with base pair coordinates, Z
p. (c) Z-scores obtained from the combination of base
pairs, Z, minus Z-scores obtained only with base-step coordinates, Z
s.
380 Nucleic Acids Research, 2008, Vol. 36, No. 2structure. The structures with the same sequence are
grouped in a cluster. For every cluster of free B-DNA
crystal structures with the same DNA sequence as the
drug-bound DNA, we calculated the average of the
Z-scores and we picked up from the annotated list in
the NDB the structures with minimum and maximum
Z-score values. The results for the cases in which drug
binding is more speciﬁc than free structures (in terms of
average Z-score) are summarized in Table 1, and the rest
of the cases are shown in Table 8 in Supplementary Data.
Almost all the drug-DNA complex structures for which a
free B-DNA crystal structure was found in NDB are
groove binders. The most populated group of DNA
sequence in Table 1 is 50-CGCGAATTCGCG-30 (37 drug-
DNA complexes and 25 B-DNA crystal structures) since
the determination of this dodecamer structure was a
milestone in structural biology (33).
In general there is more variability in Z-scores of free
B-DNA structures than in drug-bound DNA with the
same sequence, since the free B-DNA is more ﬂexible in its
conformational state than in the DNA structures bound
by a drug, that constraints the DNA movements. In
several cases, the drug-DNA complexes give higher
speciﬁcity (more negative Z-score) than the average
value of the Z-scores corresponding to free B-DNA
crystal structures with the same DNA sequence (column
Zave). This indicates that the DNA conformation plays an
important role in the recognition by such drugs.
The Z-scores of the drug-DNA complex structures for
which an analogous free B-DNA crystal structure in NDB
with the same DNA sequences was not found are shown in
Supplementary Data (Table 6 for groove binders and
Table 7 for intercalators). In almost all the drug-DNA
complexes, the Z-scores are negative, indicating that the
DNA conformational state after the drug binding still
depends on the DNA sequence. In the absence of a free
DNA structure, we cannot estimate the signiﬁcance of the
DNA conformation for the speciﬁcity of drug-DNA
recognition. Nevertheless, the sequence dependence of
the DNA conformational state may play an important
role in the DNA recognition by some drugs (see the next
section), in addition to the direct interactions between
drugs and DNA.
We also calculated the Z-scores using PMFs derived
from the drug-bound structures and using the jack-knife
method we compared them with the values obtained with
PMFs derived from free B-DNA structures. We obtained
mean absolute errors (MAE) of 0.749, 0.669 and 0.702 for
base pair, base steps and the combination of both,
respectively. These results indicate that the PFMs derived
from free B-DNA and from drug-DNA binding crystal
structures are not equivalent. One of the reasons of such
divergence is that we need to relax the constraint of using
only steps with B conformation to produce enough
number of samples (at least six) for each conformational
state, while deriving the PFMs from drug-bound struc-
tures. It would be interesting to improve the speciﬁcity in
our approach by deriving PMSs from intercalator and
groove binder drug complexes independently. However,
the aforementioned lack of data limits such technique at
present.
Visualization of theposition-dependent Z-scoreswith
‘worm’ graphs
The conformational energies and Z-scores can be
calculated not only for the whole DNA sequence but
also for each base pair and for each base step of the DNA
strands. This enables us to obtain more detailed informa-
tion of the way the conformational changes aﬀect the
energy distribution within the DNA structure. The
Z-scores of the conformational energy for each base pair
Table 1. Z-scores of the drug dataset and Z-scores of the available free PDB structures with the same DNA sequence as the drug-bound DNA
Sequence Drug PDB Z PDBm Zm PDBM ZM NZ ave
CCAATTGG Netropsin 1z8v  2.85 431d  2.84 431d  2.84 1  2.84
CCAGGCCTGG Imidazole-pyrrole 365d  2.68 1cw9  3.16 1bd1  1.77 5  2.50
CGCATATTTGCG Tri-benzimidazole 459d  2.49 458d  2.00 458d  2.00 1  2.00
CGCGAATTCGCG m-iodo Hoechst 443d  3.43 428d  4.18 270d  2.24 25  3.33
CGCGAATTCGCG m-iodo Hoechst 449d  3.51 428d  4.18 270d  2.24 25  3.33
CGCGAATTCGCG Benzimidazole 453d  3.65 428d  4.18 270d  2.24 25  3.33
CGCGAATTCGCG Benzimidazole 1ftd  3.57 428d  4.18 270d  2.24 25  3.33
CGCGAATTCGCG Benzimidazole 1qv4  3.33 428d  4.18 270d  2.24 25  3.33
CGCGAATTCGCG Thiophene diamidine 1vzk  3.67 428d  4.18 270d  2.24 25  3.33
CGCGAATTCGCG Propamidine 1prp  3.54 428d  4.18 270d  2.24 25  3.33
CGCGAATTCGCG Oxapentamidine 166d  3.52 428d  4.18 270d  2.24 25  3.33
CGCGAATTCGCG Netropsin 6bna  3.86 428d  4.18 270d  2.24 25  3.33
CGCGAATTCGCG Netropsin 101d  3.54 428d  4.18 270d  2.24 25  3.33
GCGCGC Triostin 0dac  2.78 1d97  1.69 1d97  1.69 1  1.69
GCGTACGC Quinoxaline 1pfe  3.97 253d  2.43 253d  2.43 1  2.43
GCGTACGC Echinomycin 1xvk  2.88 253d  2.43 253d  2.43 1  2.43
GTATATAC Netropsin 473d 1.63 446d 1.77 446d 1.77 1 1.77
Notes: The columns PDB and Z show the PDB ﬁle name of the DNA-drug complex and the respective Z-score value; PDBm and Zm give the PDB
ﬁle name of the free B-DNA crystal structure and the Z-score with the minimum Z-score value; PDBM and ZM show the PDB ﬁle name and Z-score
value of the free B-DNA crystal structure with the maximum Z-score. The column N shows the number of the free B-DNA crystal structures with
the same DNA sequence, and the column Zave shows the average of the Z-scores of all the free B-DNA crystal structures with the same DNA
sequence as the drug-bound DNA.
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conformational state on the sequence of its building bases.
To get an insight into the contribution of speciﬁcity
associated with sequence and conformation within a given
DNA structure in a more visual manner, we use ‘worm’
graphs (19). The ‘worm’ graphs show the distribution of
the speciﬁcity mapped on the 3D structure of the DNA
strand in a color codiﬁcation. In these graphs, the C1
atoms of the nucleotides are used to represent the DNA
backbone. These atoms are drawn as spheres, with the
color representing the Z-score value of the corresponding
base pair. The base steps are represented by cylinders
connecting the spheres that represent the base pairs. The
radii of the cross sections of the cylinders are half of the
radii of the adjoining spheres, the color codifying the value
of the base-step Z-scores; high Z-scores (low speciﬁcity) in
red and low Z-scores (high speciﬁcity) in blue. The global
Z-scores of the drug-DNA complexes can be larger than
of the free DNA with the same sequence, but the ‘worm’
graphs reveal the exact position of the DNA structure
contributing to the binding speciﬁcity as shown in the
following examples.
Imidazole-pyrrole-hydroxypyrrole polyamide. Polyamides
containing imidazole and pyrrole carboxamides are
the synthetic counterpart with promising anticancer
properties (34) of the natural netropsin and distamycin
A, two antiviral drugs. The left panels of Figure 3 show
the Z-score distribution of a DNA structure with
sequence 50-CCAGTACTGG-30 bound by imidazole-
pyrrole-hydroxypyrrole (Im/Py/Hp) polyamide (top), and
the Z-score distribution of the corresponding free B-DNA
crystal structure with minimum Z-scores (bottom). The
comparison of the two panels shows that although in this
case the drug binding increases the global conformational
energy Z-scores, the drug binding reduces the Z-scores
along local regions that expand further from the vicinity
of the native sequence, T-A, to which the drug was
designed to bind. In particular, it reduces the Z-score of the
T-base pair energy with respect to the free DNA structure
with minimum energy. The binding process produces a
slight reduction in the global conformational energy
Z-scores, but more dramatic distortion happens to the
base-step Z-score distribution.
m-Iodo, p-methoxy Hoechst. Halogenated DNA precur-
sors are important in cancer radiotherapy since they
sensitize local DNA regions to both UV and ionization
radiation resulting in the subsequent DNA strand break-
age. This mechanism is the basis for the radiosensitizer
drug design, in which a halogen atom is incorporated
407d, Im/Py/Hp polyamide, Z= −2.10 444d,  m-iodo, p-methoxy Hoechst, Z=−3.05 
1d8g, 5′-CCAGTACTGG-3′, Z=−2.70  428d, 5′-CGCGAATTCGCG-3′, Z= −4.18 
Z  
Figure 3. ‘Worm’ graph representations of drug-DNA crystal structures (top) and the corresponding free B-DNA crystal structures (bottom). The
color codiﬁes the Z-score value of the energy in each dinucleotide step (the blue color indicates high speciﬁcity and the red, low). The tube passes
across the backbone formed by the C1 carbons of each nucleotide. The terminal bases are represented with black spheres and the terminal steps, for
which the Z-scores are not calculated, with thin black lines. The subindices 5 and 3 stand for terminals 50 and 30 of the DNA sequences. The ligands
and the heteroatoms are shown as ball and stick models. The color bar in the bottom represents the color codiﬁcation of the Z-scores of the
conformational energies.
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p-methoxy Hoechst is a good example of this concept (35).
The right panels of Figure 3 show the Z-score
distribution of a DNA structure with a sequence
50-CGCGAATTCGCG-30 bound by m-iodo, p-methoxy
Hoechst (top), and the Z-score distribution of the
corresponding free B-DNA crystal structure with max-
imum Z-scores (bottom). m-Iodo, p-methoxy Hoechst is
designed to bind to T-A sequences. The comparison
between the drug-bound and the drug-free conformational
states shows that the base-pair and base-step Z-score
energies of the central T-A bound by the drug are very
similar in the bound structure and in the free B-DNA
structure with minimum global Z-scores. But in the
neighborhood of the T-A, the base-pair and base-step
Z-score energies are lower for the drug-DNA complex.
This drug also induces a reduction in the base-step
Z-scores in the vicinity of the binding region.
Echinomycin. Echinomycin (also known as quinomycin A)
is a depsipeptide antibiotic and the canonical representa-
tive of the quinoxaline antibiotics that are antitumor
agents and act by binding to DNA via the mechanism
of bi-functional intercalation, interfering with both
replication and transcription (36). The top-left panel of
Figure 4 shows the Z-score distribution of a DNA
structure with sequence 50-ACGTACGT-30 bound by
echinomycin. The structure has the expected (36)
Hoogsteen pairing for the T-A base pairs ﬂanking the
intercalating chromophores, and Watson–Crick pairing
for both C-G base pairs enclosed by the drug. The
Hoogsteen pair has less speciﬁcity (higher Z-scores) than
the C-G base pairs. These results agree with the fact that
echinomycin has long been known to bind best to GC-
rich DNAs (37), and with the idea that echinomycin
induces structural changes in regions, surrounding its
binding site, and that these changes can be cooperatively
propagated over several turns of the DNA helix (38).
Various enzymatic and chemical probes have conﬁrmed
that echinomycin can induce DNA structural changes in
regions remote from their actual binding sites (37).
Chromomycin A3. Chromomycin A3 (also known as
aburamycin B and toyomycin) is a glycosidic antineoplas-
tic antibiotic of the aureolic family used clinically in
cancer therapies. It reversibly binds to G-C base pairs in
the minor groove of DNA, thereby inhibiting RNA
synthesis (39). It is a potent inhibitor of neuronal
1xvn, Echinomycin, Z = −2.67
5′-ACGTACGT-3′
1vaq, ChromomycinA3, Z = −2.19
5′-TTGGCCAA-3′
198d,Idarubicin, Z = −2.11
5′-CGATCG-3′
1d33, Daunorubicin, Z = −2.76
5′-CGCGCG-3′
Z
Figure 4. ‘Worm’ graph representations of drug-DNA crystal structures without corresponding free B-DNA crystal structures. The color codiﬁcation
is the same as in Figure 3.
Nucleic Acids Research,2008, Vol. 36,No. 2 383apoptosis induced by oxidative stress, by a mechanism
proposed to be due to the inhibition of the binding of
transcription factors Sp1 and Sp3 to their cognate
‘G-C’ box (40).
The top-right panel of Figure 4 shows the Z-score
distribution along a DNA structure with sequence
50-TTGGCCAA-30 bound by chromomycin A3. The
central G-C pair has high speciﬁcity that is reduced
gradually in the strand tails, which could be due to both
the lowest speciﬁcity of the A and T bases, and the
boundary eﬀect in the strand terminals.
Idarubicin. Idarubicin (Idamycin) is an analog of dau-
norubicin but 5 to 6 times more potent and less
cardiotoxic than daunorubicin. The mechanism of action
of the anthracyclines (doxorubicin, daunorubicin and
idarubicin) is poorly understood. Cytotoxicity is generally
attributed to intercalation of the drug into DNA and
inhibition of DNA topoisomerase II activity resulting in
double- and single-strand DNA breaks. Idarubicin is used
to treat a broad spectrum of solid and hematologic
cancers (41).
The bottom-left panel of Figure 4 shows the Z-score
distribution of a DNA structure with sequence
50-CGATCG-30bound by idarubicin. The A-T base pairs
not involved in the intercalation display a low buckle
angle, which diﬀers from those of the base pairs
aﬀected by the drug intercalation. This is reﬂected in the
lower speciﬁcity of the central A and T base pairs (greener
spheres). At the intercalation steps, the idarubicin
molecules unwind the DNA, the helical twist angles
between A(3)-T(10)/T(4)-A(9) decrease by almost 7.58
from the B-DNA standard value of 368 (42), shown in the
‘worm’ graph with bluer cylinders between the A and the
T bases.
Daunorubicin. Daunorubicin (or daunomycin) as idarubi-
cin is a chemotherapy agent of the anthracycline family. It
is most commonly used to treat speciﬁc types of leukemia.
On binding to DNA, daunomycin intercalates, with its
daunosamine residue directed towards the minor groove.
It has the highest preference for the two adjacent G/C base
pairs ﬂanked on the 50 side by an A/T base pair (43).
Daunomycin eﬀectively binds to every 3 base pairs and
induces a local unwinding angle of 118, but has negligible
distortion of helical conformation (44). The bottom-right
panel of Figure 4 shows the Z-score distribution of a DNA
structure with sequence 50-CGCGCG-30 bound by
daunorubicin and is very similar to that of the other
anthracycline (idarubicin) in the left panel.
The above examples show how the compensation of the
increments and decrements of the local Z-scores some-
times masks the distribution of the conformational
change due to the drug binding, producing similar
global Z-scores. Therefore, it is important to analyze the
Z-score distribution along the DNA structure, and tools
like the ‘worm’ graphs help to accomplish such a task.
Before binding of drug, the free DNA structures have an
approximately uniform Z-score distribution. After bind-
ing, this distribution acquires more contrast. We can
interpret the decrease in the Z-scores (increase of
speciﬁcity) upon binding as a result of DNA conforma-
tional changes more suitable for the speciﬁc binding of the
drug. The increase in the Z-scores means a local loss of
speciﬁcity, which could be due to the extra strain caused
by direct interactions between drug and DNA. The drug
binding not only aﬀects the closest bases, changing their
conformational states, but also induces long-range
changes in the conformational energies. Similar phenom-
enon is well known from the indirect readout mechanism
in protein-DNA complexes, where protein binding induces
distortion of the DNA conformation (45). The direct and
indirect readouts can be viewed as intermolecular and
intramolecular processes, respectively (46), and their
balance may be important for both protein-DNA and
drug-DNA recognitions.
CONCLUSIONS
When drugs bind to DNA, they usually change the DNA
conformation to some degree. However, changes in DNA
conformation and global energy may not be directly
relevant to the sequence speciﬁcity. What is important in
the drug-DNA recognition process is the sequence
dependence of conformation and energy, which may be
very subtle. The sequence-structure threading technique
enabled us to estimate the Z-scores of the conformational
energy as a measure of the sequence speciﬁcity.
The calculated Z-scores from knowledge-based PMF
were generally negative for both intercalators and DNA
groove binders, indicating that the indirect readout
through the sequence-dependent conformational energy
of DNA can potentially contribute to the sequence
speciﬁcity of drug-DNA complex. The more negative
Z-scores for the groove binding drugs with respect to the
intercalating drugs are in agreement with previous
experimental results (32), in which intercalating drugs
are not very speciﬁc, but the groove bindings are
signiﬁcantly speciﬁc.
We have compared the Z-scores of groove-binding
drugs in complex with DNA and the corresponding free
B-DNA with the same sequence. We found that for several
cases the Z-scores of drug-DNA complexes are more
negative than those of the free B-DNAs. For other drugs,
both values are comparable or the Z-scores of the free
B-DNAs are more negative. We examined the context-
dependence of the conformational energy and the Z-scores
within those drug-DNA structures, by calculating the
distribution of Z-scores as illustrated with the ‘worm’
graphs, and showed that the conformational changes of
DNA caused by the drug binding changes signiﬁcantly
the Z-score distribution within the DNA structures, even
if the overall Z-score is not changed signiﬁcantly. Thus,
these results indicate that drugs may use the conforma-
tional change of DNA induced by the binding to increase
the speciﬁcity to recognize speciﬁc sequences in an indirect
manner.
We have proposed computational tools for the quanti-
ﬁcation of the binding speciﬁcity, together with the
automatic classiﬁcation of the drug-DNA binding mode.
These tools can help in the high-throughput screening of
384 Nucleic Acids Research, 2008, Vol. 36, No. 2possible drug candidates and in the new drugs design,
which may complement drug-DNA direct readout PMF
of Ge et al. (47).
The aim of our work was to examine the sequence
dependence of the conformational energy of DNA in
drug-DNA complexes, but not to estimate the binding free
energy of drug-DNA interactions. In order to estimate the
binding free energy, it is also necessary to evaluate the
interaction energies between drug and DNA, and solva-
tion energy, in addition to the conformational energies of
DNA computed here. For example, the enthalpy–entropy
compensation phenomena observed by the Breslauer
group in netropsin or distamycin binding to homo or
alternating AT sequences (48) might not be explained
without including the eﬀect of water in the drug-DNA
complexes.
Our approach for the analysis of the speciﬁcity of the
conformational state and its context-dependency can be
used to study the drug-DNA recognition process since the
essential movements occurring in free B-DNA should be
similar to those necessary to deform DNA in complexes.
Since Jarque–Bera hypothesis test of composite normal-
ity of the energy conformational landscape reveals that the
harmonic hypothesis is not always applicable, especially
when large deformations are involved, we plan in future
research to develop PMF based on non-harmonic models
with higher application spectrum.
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